Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas
Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas Reuters
Covered in this story
Analyst targets on Moderna
- Citi: $193 → $80 by Sep 2027 · Sell via 247wallst.com
- Rothschild & Co Redburn: $149 → $81 by Sep 2027 · Sell via Investing.com
- Morgan Stanley: $174 → $89 by Aug 2027 · Equalweight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRNA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Moderna →Dalsna Finance is currently tracking 6 stories mentioning Moderna, the earliest published 20 Aug 2026.
Summary aggregated from Reuters's public RSS feed. The full reporting belongs to Reuters — please read it on their site.